Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Consonance-Hfw Acq Corp (SRZN)

Consonance-Hfw Acq Corp (SRZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,795
  • Shares Outstanding, K 3,199
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,040 K
  • 60-Month Beta 0.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.21
Trade SRZN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -2.79
  • Number of Estimates 1
  • High Estimate -2.79
  • Low Estimate -2.79
  • Prior Year -4.65
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.30 +20.32%
on 05/20/24
11.99 -6.67%
on 06/03/24
+0.74 (+7.09%)
since 05/14/24
3-Month
8.14 +37.47%
on 04/26/24
16.19 -30.88%
on 03/28/24
-2.31 (-17.11%)
since 03/14/24
52-Week
4.50 +148.67%
on 11/09/23
16.19 -30.88%
on 03/28/24
+1.52 (+15.71%)
since 06/14/23

Most Recent Stories

More News
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

CTLT : 55.48 (-0.88%)
NRIX : 15.18 (-9.26%)
IKNA : 1.7500 (-1.13%)
SRZN : 11.19 (-0.71%)
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?

Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.

HROW : 17.97 (+0.17%)
IKNA : 1.7500 (-1.13%)
SRZN : 11.19 (-0.71%)
IVVD : 1.5800 (-7.06%)
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

CTLT : 55.48 (-0.88%)
IKNA : 1.7500 (-1.13%)
SRZN : 11.19 (-0.71%)
IVVD : 1.5800 (-7.06%)
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher

Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among...

SRZN : 11.19 (-0.71%)
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?

Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

PKI : 115.24 (-0.91%)
IKNA : 1.7500 (-1.13%)
SRZN : 11.19 (-0.71%)
IVVD : 1.5800 (-7.06%)
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.

DVA : 141.16 (-0.70%)
APTX : 0.0960 (+3.11%)
BRBR : 55.20 (-2.35%)
SRZN : 11.19 (-0.71%)
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.

BDX : 233.73 (+0.76%)
CAH : 100.20 (-0.41%)
BRBR : 55.20 (-2.35%)
SRZN : 11.19 (-0.71%)
What Awaits Lantheus Holdings (LNTH) This Earnings Season?

Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.

CAH : 100.20 (-0.41%)
LNTH : 79.26 (-1.02%)
BRBR : 55.20 (-2.35%)
SRZN : 11.19 (-0.71%)
Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity

Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article.

NSP : 92.87 (-0.12%)
NEO : 13.18 (-1.79%)
LW : 86.76 (+0.68%)
BEKE : 15.71 (-0.70%)
SRZN : 11.19 (-0.71%)
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio

Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.

LLY : 878.45 (-0.55%)
NKTR : 1.1700 (-6.40%)
LRMR : 9.39 (-3.10%)
SRZN : 11.19 (-0.71%)

Business Summary

Surrozen Inc. is a company pioneering targeted therapeutics which selectively activates the Wnt pathway for tissue repair and regeneration. Surrozen Inc., formerly known as Consonance-HFW Acquisition Corp., is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 11.66
2nd Resistance Point 11.50
1st Resistance Point 11.34
Last Price 11.19
1st Support Level 11.03
2nd Support Level 10.86
3rd Support Level 10.71

See More

52-Week High 16.19
Fibonacci 61.8% 11.72
Last Price 11.19
Fibonacci 50% 10.35
Fibonacci 38.2% 8.97
52-Week Low 4.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar